Content area

|
|

Strategier for reversering af non-vitamin K orale antikoagulantia

Forfatter(e)
Frederik Uttenthal Larsen1, Anne-Mette Hvas2, 3 & Erik Lerkevang Grove1, 3 1) Hjertesygdomme, Aarhus Universitetshospital 2) Blodprøver og Biokemi, Aarhus Universitetshospital 3) Institut for Klinisk Medicin, Aarhus Universitet Ugeskr Læger 2016;178:V03160212
Reference: 
Ugeskr Læger 2016;178:V03160212
Blad nummer: 
Sidetal: 
2-5
Reversal strategies for non-vitamin K antagonist oral anticoagulants
Non-vitamin K oral anticoagulants (NOACs) are alternatives to vitamin K antagonists and provide consistent anticoa­gulation with equal or better clinical outcome and no need for routine monitoring. Bleeding is a feared complication of anticoagulants. Until recently, no specific agent has been available for reversal of NOACs. Idarucizumab binds dabi­gatran for rapid reversal of its activity without procoagulant effects. Andexanet alpha (expected release in 2016) and PER977 are antidotes under clinical development. This article summarizes current and potential future options to anta­gonize NOACs.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Camilla Bang | 29/11
2 kommentarer
af Stine Madsen-Østerbye | 29/11
1 Kommentar
af Kaj Seidelin | 29/11
6 kommentarer
af Pedram Kazemi-Esfarjani | 28/11
2 kommentarer
af Ulf Bern Jensen | 24/11
2 kommentarer
af Bodil Marie Nielsen | 24/11
2 kommentarer
af Toke Seierøe Barfod | 23/11
2 kommentarer
af Thorkild I.A. Sørensen | 20/11
1 Kommentar
af Kim Varming | 20/11
1 Kommentar